ScoreHaematology

Smouldering myeloma progression risk (IMWG 2/20/20 and risk score)

Estimates the 2-year risk that smouldering multiple myeloma progresses to active myeloma.

Updated 31 October 2026

When to use it

Patients with smouldering myeloma (no myeloma-defining events) at diagnosis, to plan follow-up or consider early-treatment trials.

What it needs

  • Free light chain ratio (involved/uninvolved)Units: cociente
  • Serum M-proteinUnits: g/dL, g/L
  • Bone marrow plasma cells (higher of biopsy or aspirate)Units: %
  • FISH showing t(4;14), t(14;16), 1q gain or del(13q)/monosomy 13Yes or no

The points for each answer and the automatic total are in the app.

How to interpret it

IMWG risk score
ResultInterpretation
≤ 40–4: low risk (≈ 4 % at 2 years)
5–85–8: low-intermediate risk (≈ 26 % at 2 years)
9–129–12: intermediate risk (≈ 51 % at 2 years)
≥ 13> 12: high risk (≈ 73 % at 2 years)

In the app it also calculates: 2-year progression risk predicted by the score, 2/20/20 factors present, 2/20/20 factors + high-risk cytogenetics.

Practical tip

The 2/20/20 model counts three factors: M-protein > 2 g/dL, involved/uninvolved free light chain ratio > 20 and marrow plasma cells > 20 %.

3 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top